Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 28781 [2011-12194]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 96 / Wednesday, May 18, 2011 / Notices
Reason: Failed to maintain valid
bonds.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Sandra L. Kusumoto,
Director, Bureau of Certification and
Licensing.
Independent Scientific Peer Review
Panel Report: Evaluation of the
Validation Status of an In Vitro
Estrogen Receptor Transcriptional
Activation Test Method for Endocrine
Disruptor Chemical Screening: Notice
of Availability and Request for Public
Comments
[FR Doc. 2011–12222 Filed 5–17–11; 8:45 am]
BILLING CODE 6730–01–P
FEDERAL RESERVE SYSTEM
srobinson on DSKHWCL6B1PROD with NOTICES
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The application also will be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than June 13, 2011.
A. Federal Reserve Bank of San
Francisco (Kenneth Binning, Vice
President, Applications and
Enforcement) 101 Market Street, San
Francisco, California 94105–1579:
1. BankGuam Holding Company, to
become a bank holding company by
acquiring 100 percent of Bank of Guam,
both of Hagatna, Guam, and also elects
to become a financial holding company.
Board of Governors of the Federal Reserve
System, May 13, 2011.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2011–12194 Filed 5–17–11; 8:45 am]
Division of the National
Toxicology Program (DNTP), National
Institute of Environmental Health
Sciences (NIEHS), National Institutes of
Health (NIH).
ACTION: Notice of availability and
request for comments.
AGENCY:
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The NTP Interagency Center
for the Evaluation of Alternative
Toxicological Methods (NICEATM), on
behalf of the Interagency Coordinating
Committee on the Validation of
Alternative Methods (ICCVAM),
convened an independent international
scientific peer review panel (hereafter,
Panel) on March 29–30, 2011, to
evaluate the validation status of the
LUMI–CELL® (BG1Luc ER TA) test
method, an in vitro transcriptional
activation (TA) assay used to identify
chemicals that can interact with human
estrogen receptors (ERs). The Panel
report is now available on the
NICEATM–ICCVAM Web site at: https://
iccvam.niehs.nih.gov/docs/endo_docs/
EDPRPRept2011.pdf or by contacting
NICEATM (see ADDRESSES). The report
contains (1) the Panel’s evaluation of the
validation status of the test method and
(2) the Panel’s comments on the draft
ICCVAM test method recommendations.
NICEATM invites public comment on
the Panel report.
DATES: Written comments on the Panel
report should be received by July 5,
2011.
SUMMARY:
NICEATM prefers that
comments be submitted electronically
by e-mail to niceatm@niehs.nih.gov.
Comments can also be submitted via the
NICEATM–ICCVAM Web site at https://
iccvam.niehs.nih.gov/contact/FR_
pubcomment.htm. Written comments
can be sent by mail or fax to Dr. Warren
Casey, Deputy Director, NICEATM,
NIEHS, P.O. Box 12233, Mail Stop: K2–
16, Research Triangle Park, NC 27709;
(fax) 919–541–0947. Courier address:
NIEHS, NICEATM, 530 Davis Drive,
Room 2035, Durham, NC 27713.
FOR FURTHER INFORMATION CONTACT: Dr.
Warren Casey: (telephone) 919–316–
4729, (fax) 919–541–0947, (e-mail)
niceatm@niehs.nih.gov.
ADDRESSES:
BILLING CODE 6210–01–P
VerDate Mar<15>2010
16:31 May 17, 2011
Jkt 223001
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
28781
SUPPLEMENTARY INFORMATION:
Background
In January 2011, NICEATM
announced the convening of an
independent scientific peer review
panel to review and comment on the
draft background review document
(BRD) summarizing available data,
reliability and accuracy of the BG1Luc
ER TA test method, the draft
recommendations, as well as the
availability of the draft documents for
public comment (76 FR 4113). The
Panel met in public session on March
29–30, 2011, at the Natcher Conference
Center in Bethesda, MD. The Panel
reviewed the draft ICCVAM BRD for
completeness, errors, and omissions of
any existing relevant data or
information. The Panel also evaluated
the information in the draft documents
to determine the extent to which each
of the applicable criteria for validation
and acceptance of toxicological test
methods (ICCVAM, 2003a) had been
appropriately addressed. The Panel then
considered the ICCVAM draft
recommendations and commented on
the extent that the recommendations
were supported by the information
provided in the draft BRD.
In January 2004, Xenobiotic Detection
Systems, Inc. (XDS, Durham, NC)
nominated their LUMI–CELL® BG1Luc
ER TA test method for an
interlaboratory validation study. This
method uses BG–1 cells, a human
ovarian carcinoma cell line that is stably
transfected with an estrogen-responsive
luciferase reporter gene to measure
whether and to what extent a substance
induces or inhibits TA activity via ER
mediated pathways (Denison and HeathPagliuso, 1998). Included in the
nomination package were test results
from XDS for 56 of the 78 ICCVAM
reference substances for agonist activity
and 16 of the 78 ICCVAM reference
substances for antagonist activity. These
studies were funded primarily by an
NIEHS Small Business Innovation
Research (SBIR) grant
(SBIR43ES010533–01).
In accordance with the ICCVAM
nomination process, NICEATM
conducted a preliminary evaluation of
the nomination package to determine
the extent to which it addressed the
ICCVAM prioritization criteria and
adherence to the ICCVAM
recommendations for the
standardization and validation of in
vitro endocrine disruptor test methods
(ICCVAM, 2003b). ICCVAM and the
Scientific Advisory Committee on
Alternative Toxicological Methods
(SACATM) recommended that the
BG1Luc ER TA test method should be
E:\FR\FM\18MYN1.SGM
18MYN1
]]>Agencies
[Federal Register Volume 76, Number 96 (Wednesday, May 18, 2011)]
[Notices]
[Page 28781]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-12194]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C.
1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The applications listed below, as well as other related filings
required by the Board, are available for immediate inspection at the
Federal Reserve Bank indicated. The application also will be available
for inspection at the offices of the Board of Governors. Interested
persons may express their views in writing on the standards enumerated
in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the
acquisition of a nonbanking company, the review also includes whether
the acquisition of the nonbanking company complies with the standards
in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted,
nonbanking activities will be conducted throughout the United States.
Unless otherwise noted, comments regarding each of these
applications must be received at the Reserve Bank indicated or the
offices of the Board of Governors not later than June 13, 2011.
A. Federal Reserve Bank of San Francisco (Kenneth Binning, Vice
President, Applications and Enforcement) 101 Market Street, San
Francisco, California 94105-1579:
1. BankGuam Holding Company, to become a bank holding company by
acquiring 100 percent of Bank of Guam, both of Hagatna, Guam, and also
elects to become a financial holding company.
Board of Governors of the Federal Reserve System, May 13, 2011.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2011-12194 Filed 5-17-11; 8:45 am]
BILLING CODE 6210-01-P
